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Background: Low lung function is associated with increased morbidity and mortality. It is therefore of interest to
identify biomarkers that are associated with impaired lung function. The aim of the study was to analyse
associations of biomarkers and combinations of biomarkers with lung function in an elderly general population.
Methods: Lung function (FEV1 and FVC) and a panel of 15 inflammatory markers from blood samples were
analysed in 888 subjects aged 70 years. Biomarkers included cytokines, chemokines, adhesion molecules, C-reactive
protein (CRP) and leukocyte count.
Results: Leukocyte count and CRP were independently associated with FEV1 after adjustments for other
inflammatory markers, sex, BMI, current smoking and pack-years of smoking. In a similar model, leukocyte count
and vascular cell adhesion protein 1 (VCAM-1) were the biomarkers that were significantly associated with FVC.
Subjects that had both leukocyte count and CRP in the lowest tertile had a FEV1 that was 9% of predicted higher
than subjects with leukocyte count and CRP in the highest tertile (103±16 vs. 94±21% of predicted, p=0.0002)
(mean±SD). A difference of 8% of predicted in FVC was found between subjects with leukocyte count and VCAM-1
in the lowest and highest tertiles, respectively (106±18 vs. 98±19% of predicted, p=0.002).
Conclusion: Leucocyte count, CRP and VCAM-1 were found to relate to poorer lung function. A dose related
association was found for the combination leukocyte count and CRP towards FEV1 and leukocyte and VCAM-1
towards FVC. This indicates that combination of two biomarkers yielded more information than assessing them one
by one when analysing the association between systemic inflammation and lung function.
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Lung function is characterized by slow and irreversible
age-related decline. The rate of decline can be accelerated
by several factors, e.g. smoking, environmental exposure
or lung disease. Lung function is often assessed by meas-
uring forced expiratory volume in 1 second (FEV1) and
forced vital capacity (FVC). Having a low FEV1 has been
shown to be related to all-cause mortality [1] and car-
diovascular mortality [2], while a low FVC has been
associated with higher risk of developing diabetes [3] and
myocardial infarction [4]. Low FEV1 and FVC are both* Correspondence: christer.janson@medsci.uu.se
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distribution, and reproduction in any mediumrelated to a higher prevalence of hypertension [5] and a
higher risk of mortality in patients with chronic heart fail-
ure [6]. In one study FVC was found to be more strongly
related to survival than FEV1 [7].
As low lung function is an indicator for increased
morbidity and mortality, it is of great interest to identify
and validate biomarkers that are associated with impaired
lung function. Many serum-biomarkers have been pro-
posed to have relationship with lung function, whereof
particularly inflammatory serum-biomarkers such as
C-reactive protein (CRP), leukocyte count, fibrinogen, and
interleukin (IL)-6 have been related to chronic obstructive
pulmonary disease (COPD) and reduced FEV1 [8-12].
These markers probably reflect both the inflammatory
activity in the lungs and an underlying systemic low-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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lot between studies and it is not possible yet to establish
a particular biomarker with adequate relation to lung
function. Some studies indicate that assessing combin-
ation of biomarkers may be more useful when investiga-
tion correlation to lung function [13] or prognosis [14,15].
Several studies indicate a stronger association between
biomarker-level and impaired lung function in men than
in women [16-19]. It is therefore important to include
gender aspects when investigating the association of
biomarker-levels to lung function.
The aim of this study was to analyse association be-
tween inflammatory biomarkers and lung function in an
elderly population and to investigate whether there was
a gender-specific difference in this association.
Methods
Study population
The design of the Prospective Investigation of Vasculature
in Uppsala Seniors study (PIVUS) has been published in
detail [20]. In the study, 2,025 subjects aged 70 years
were randomly selected from the general population of
Uppsala, Sweden. Participation rate was 50.1% (1016
participants). As the participation rate was moderate,
cardiovascular disorders and medication in 100 consecu-
tive non-participants were evaluated. The prevalence of
cardiovascular drug intake, history of myocardial infarc-
tion, coronary revascularisation, antihypertensive medi-
cation, statin use, and insulin treatment were similar to
in the sample investigated, whereas, the prevalence of
diabetes, congestive heart failure and stroke tended to
be higher among the non-participants. The study was
approved by the Ethic Committee at the University of
Uppsala, and all participants gave informed consent.
Clinical investigations
Participants completed a questionnaire concerning med-
ical history, regular medication use and smoking habits.
All subjects were examined the morning after an over-
night fast, and no medication or smoking was allowed
after midnight. After recording height, weight, abdominal
and hip circumference, blood samples were taken and
analysed by standard laboratory techniques. Subjects were
categorised as never-smokers, ex-smokers or current
smokers and pack years of smoking was calculated. BMI
was calculated as weight in kilograms divided by the
square of the height in metres.
Spirometry
As previously reported [18,21], spirometry was performed
with a Vitalograph Alpha spirometer (Vitalograph Ltd.
Buckingham, UK), in accordance with the American
Thoracic Society recommendations [22]. The best value of
three recordings was used. FEV1 and FVC values wereexpressed as per cent of predicted values, adjusted for age,
gender and height. Predicted values for FEV1 were based on
the European Coal and Steel Union reference values [23].
Biomarkers
The analysis of cytokines, chemokines and adhesion mole-
cules in blood has been described previously [24]. The
panel of analysed biomarkers included CRP, leukocyte
count, monocyte chemotactic protein (MCP)-1, interleu-
kin (IL)-1α, IL1β IL-2, IL-4, IL-6, IL-8, IL-10, Interferon
gamma (IFN γ), tumour necrosis factor alpha (TNF-α),
epidermal growth factor (EGF), vascular endothelial
growth factor (VEGF), vascular cell adhesion protein 1
(VCAM-1), intercellular adhesion molecule 1 (ICAM-1),
E-selectin, P-selectin, and L-selectin.
High sensitive CRP was measured in human serum by
an ultrasensitive particle enhanced immunoturbidimetric
assay (Orion Diagnostica, Espoo, Finland) on a Konelab 20
autoanalyser (Thermo Clinical Labsystems, Espoo, Finland).
The interassay coefficient of variation was 3.2%.
Cytokines, chemokines and adhesion molecules were
analysed on the Evidence® array biochip analyser (Randox
Laboratories Ltd., Crumlin, UK) [25]. The intra-assay
coefficient of variation was 6.9–15.0% and the interassay
coefficient of variation was 8.0–16%. The functional
sensitivity for the different inflammatory markers were
IL-2, 4.1 ng/L IL-6, 0.3 ng/L, IL-8, 1.5 ng/L; IFN γ,
1.8 ng/L; TNF-α, 1.8 ng/L; MCP-1, 19.4 ng/L; ICAM-1,
18.6 ng/L; VCAM-1, 3.1 ng/L; E-selectin, 3.1 ng/L; P-
selectin, 11.2 ng/L; L-selectin, 32.8 ng/L; CRP, 0.1 mg/L;
and, leukocyte count, 0.2 x 109.
The informative value of the levels of IL-1α, IL-1β, IL-4
and IL-10 was limited, because the sensitivity of the
applied Evidence® array appeared insufficient for these
biomarkers, with more than half of the values below
detection limit. These variables were therefor not in-
cluded in the analyses.
Cardiovascular comorbidity
The following comorbidities were included in the ana-
lyses: hypertension (using medication against hyper-
tension, myocardial infarction and stroke (having been
hospitalised because of myocardial infarction or stroke).
Statistics
Statistical analyses used STATA 12 software (Stata Corp.,
College Station, Texas, USA). All variables, except FEV1,
FVC and leukocyte count, were log-transformed to ob-
tain a normal distribution. Simple linear regression was
used to assess the association of biomarkers with FEV
and FVC. The independent relationship between bio-
markers that were significantly associated with FEV1 or
FVC in the univariate analyses and lung function were
analysed by multiple linear regression with adjustment
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of smoking. As there were 84 missing values for pack-
years, STATA mi-commands were used for multiple
imputation of the missing data. Models were also made
with adjustments for cardiovascular comorbidity. The
biomarkers were standardised to one SD in all regres-
sion models. Biomarkers that were significantly associ-
ated with lung function in the final multivariable model
were grouped into tertiles in order to study the added
value of analysing two biomarkers simultaneously, and
in order to accommodate non-linear associations. Ana-
lyses stratified for gender were performed, and analyses
of interactions between gender and biomarker levels were
done. P<0.05 was considered statistically significant.
Results
Characteristics of the study population
Data on spirometry was available in 888 participants, and
the characteristics of the study population are presented










FEV1 % predicted 96±20
FVC (L) 3.85±0.70
FVC % predicted 95±16
Leukocyte count (x109/L) 5.8±1.5
CRP (mg/L) 1.2 (1.1-1.4)
MCP-1 (ng/L) 368 (355–381)
IL-2 (ng/L) 4.6 (4.2-4.9)
IL-6 (ng/L) 7.0 (6.0-8.1)
IL-8 (ng/L) 6.3 (5.9-6.7)
INF γ (ng/L) 1.8 (1.7-1.9)
TNFα (ng/L) 4.2 (4.0-4.4)
EGF (ng/L) 20.6 (18.7-22.8)
VEGF (ng/L) 161 (150–174)
VCAM-1 (μg/L) 540 (529–552)
ICAM-1 (μg/L) 346 (339–354)
E-selectin (μg/L) 15.0 (14.5-15.5)
P-selectin (μg/L) 99.2 (96.0-102)
L-selectin (μg/L) 688 (676–700)Biomarker and lung function
Univariate analysis
The association between values for 15 biomarkers and FEV1
and FVC was analysed with linear regression. Leukocyte
count, CRP and E-selectin had a negative and EGF a positive
association with the two lung function parameters (Table 2).
ICAM-1 and VCAM-1 were negatively associated with
FEV1 and FVC, respectively. Otherwise, no major asso-
ciations were found between the different biomarkers
and lung function.
Multivariate analyses
The independent associations between different bio-
markers and lung function were studied with multiple
linear regression. No significant association between
E-selectin and FEV1 or FVC was found after adjusting
for the other biomarkers that were significant associated
with lung function in the univariate model. Leukocyte
count and CRP remained statistically associated with FEV1
after further adjustments for sex, BMI, current smoking%)
Women (n=456) All subjects (n=888)












1.4 (1.3-1.5) 1.3 (1.2-1.4)
366 (353–380) 367 (358–377)
5.0 (4.6-5.4) 4.8 (4.5-5.0)
5.8 (5.0-6.8) 6.4 (5.7-7.1)
6.6 (6.2-7.0) 6.4 (6.2-6.7)
1.9 (1.8-2.0) 1.8 (1.8-1.9)
4.0 (3.8-4.2) 4.1 (3.9-4.2)
24.2 (22.0-26.5) 22.4 (20.9-23.9)
191 (177–206) 176 (167–185)
508 (497–520) 524 (515–532)
354 (345–362) 350 (345–356)
13.9 (13.3-14.4) 14.4 (14.0-14.8)
95.7 (93.2-98.3) 97.4 (95.4-99.5)
731 (718–744) 709 (701–718)
Table 2 Association between inflammatory markers and FEV1 or FVC when analysed by simple linear regression analysis
FEV1 (% predicted) p-value FVC (% predicted) p-value
Leukocyte count −3.39 (−4.68, -2.11) <0.0001 −2.44 (−3.63, -1.26) <0.0001
CRP −2.67 (−3.96, -1.38) <0.0001 −1.51 (−2.70, -0.32) 0.01
EGF 1.42 (0.12, 2.71) 0.03 1.65 (0.47, 2.84) 0.006
VCAM-1 −1.17 (−2.46, 0.13) 0.08 −2.14 (−3.33, -0.96) <0.0001
ICAM-1 −2.49 (−3.78, -1.20) <0.0001 −1.16 (−2.35, 0.03) 0.06
E-selectin −1.63 (−2.92, -0.33) 0.01 −1.84 (−3.03, -0.65) 0.002
MCP-1 0.44 (−0.86, 1.74) 0.50 0.51 (−0.69, 1.70) 0.41
IL-2 0.20 (−1.10, 1.50) 0.76 0.17 (−1.02, 1.37) 0.78
IL-6 −0.19 (−1.51, 1.12) 0.77 −1.01 (−2.22, 0.19) 0.10
IL-8 −0.47 (−1.78, 0.83) 0.48 −0.80 (−2.00, 0.39) 0.19
INF γ 0.13 (−1.18, 1.43) 0.85 −0.20 (−1.40, 0.99) 0.74
TNFα 0.01 (−1.29, 1.31) 0.99 −0.74 (−1.94, 0.45) 0.22
VEGF −0.34 (−1.64, 0.96) 0.61 0.55 (−0.65, 1.74) 0.37
P-selectin −0.75 (−2.05, 0.55) 0.26 −0.54 (−1.73, 0.66) 0.34
L-selectin 0.78 (−0.52, 2.08) 0.24 0.53 (−0.66, 1.73) 0.38
Values are β-coefficient (95% CI), in % per 1 SD change in biomarker. Markers that are significantly associated with lung function are presented in the first part of
the table.
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count and VCAM-1 were the biomarkers significantly asso-
ciated with FVC. FEV1 and FVC were also significantly
associated with female gender and pack years, while current
smoking and BMI were independently associated with FEV1
and FVC, respectively (Table 3). The associations above
remained significant after further adjustment for hyper-
tension, myocardial infarction and stroke.
Figures 1 and 2 present the mean FEV1 and FVC when
combining the two biomarkers that were predominantly
associated with each lung function variable. Subjects that
had leukocyte count and CRP in the lowest quartile had
a FEV1 that was 9% of predicted higher than subjects
with leukocyte count and CRP in highest tertile (103±
16 vs. 94±21% of predicted, p=0.0002) (mean±SD). ATable 3 Association between inflammatory markers and lung
FEV1 % predicted p
Leukocyte count −1.64 (−3.03, -0.24)
CRP −1.71 (−3.09, -0.32)
EGF 1.23 (−0.002, 2.46)
VCAM-1* -
ICAM-1** −0.97 (−2.30, 0.36)
Women 3.42 (0.90-5.94)
BMI 0.05 (−0.26,0.36)
Current smoking −6.61 (−11.2,-1.99)
Pack years −0.30, (−0.41, -0.18) <
All estimates are adjusted for each of the included inflammatory markers, pack yea
Values are β-coefficient (95% CI), in % per 1 SD change in biomarker.
* Only included in model with FVC as dependent variable.
** Only included in model with FEV1 as dependent variable.difference of 8% of predicted in FVC was found between
subjects leukocyte count and VCAM-1 in the lowest and
highest tertiles respectively (106±18 vs. 98±19% of pre-
dicted, p=0.002) (mean+SD).Gender differences
The association between leukocytes and FEV1 was statis-
tically stronger in men than in women (Figure 3). The
association between CRP and FEV1 and leukocytes and
FVC was numerically stronger in men than women while
the opposite was found for the association between
VCAM-1 and FVC, but none of these differences were
statically significant when analysed with test of inter-
action (Figures 3 and 4).function
-value FVC % predicted p-value
0.02 −1.77 (−2.96, -0.58) 0.005
0.02 -
0.05 1.05 (−0.06, 2.15) 0.06
−1.28 (−2.45, -0.11) 0.03
0.13 -
0.008 11.8 (9.54, 14.1) <0.0001
0.70 −0.29 (−0.56, -0.02) 0.04
0.005 −0.21 (−4.27, 3.86) 0.96
0.0001 −0.15 (−0.24, -0.04) 0.005












Figure 1 FEV1 (% predicted) in participants divided by tertile of
leukocyte count (<4.1, 4.1-6.0, >6.0 x109/L) and tertitles of C-reactive
protein (CRP) (<0.78, 0.78-1.8, >1.8 mg/L).
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In this study, a large number of biomarkers and their
association to lung function in a population-based sam-
ple of 70-year old men and women were analysed. A
high number of circulating leukocytes and a high level
of CRP were independently related to lower FEV1, while
a high leucocyte count and high level of circulating
VCAM-1 was associated with a lower FVC.
The relationship between higher levels of inflamma-
tory biomarkers and lower lung function in the present
study are in accordance with what has been found in













Figure 2 FVC (% predicted) in participants divided by tertile of
leukocyte count (<4.1, 4.1-6.0, >6.0 x109/L) and tertitles of
VCAM-1 (<470, 470–570, >570 μg/L).the results of these studies have been very varied regard-
ing which particular biomarker was related to which
specific lung function parameter. We found a significant
association between CRP, leukocyte count and lung func-
tion. This in accordance with several longitudinal studies
that have found an association between the rate of FEV1
decline and leukocyte count [29] and CRP [19,30]. On the
other hand we did not find an association between lung
function and IL-6 which is in contrast what has been
found in some other studies [11,16]. The lack of associ-
ation between Il-6 and lung function in the present study
is difficult to explain, as IL-6 and CRP are closely related
in the inflammatory pathway, IL-6 stimulating the hepatic
production of CRP.
In the present study circulating levels of ICAM-1 and
particularly VCAM-1 were negatively related to lung func-
tion. To some extent this finding is not surprising as both
ICAM-1 and VCAM-1 facilitate the recruitment and mi-
gration of inflammatory cells such as neutrophils from
the blood to the airway walls. Previous studies have
found higher levels of circulating adhesion molecules in
COPD patients [31] and having high levels of ICAM-1
and VCAM-1 was related to higher airway resistance
in asthma in one study [32]. We have, however, been
unable to find previous general population studies show-
ing an association between high levels of circulating adhe-
sion molecules and lung function.
The combination of leukocyte count and CRP showed
a dose response trend towards lower FEV1 whereas the
combination of leukocyte count and VCAM-1 showed a
similar trend towards FVC. This supports the idea that
assessing a combination of biomarkers may be more
informative than assessing them one by one. In the
Woman’s Health and Aging Studies, a population based
study on about thousand elderly women; the combined
highest levels of IL-6 and CRP were associated with the
lowest levels of FEV1 and FVC [13]. A combination of
several serum biomarkers has also been used to improve
the prediction of mortality and risk for comorbidities in
COPD. In the ECLIPSE study, the addition of a panel of
10 inflammatory biomarkers to the clinical variables im-
proved the ability to predict mortality in COPD signifi-
cantly [14]. The data of two large Danish population
studies indicate that simultaneously elevated levels of
CRP, fibrinogen and leukocyte count are associated with
a two- to fourfold risk of major comorbidities (e.g. myo-
cardial infarction, lung cancer) in COPD [15].
In the present study smoking and BMI were as expected
associated with lung function. Both these variables are
also associated with systemic inflammation [33,34]. It
was therefore important to adjust for smoking status
and BMI in our final models. Inflammatory biomarkers
like CRP are also associated with cardiovascular diseases











Men Women Men Women
FEV1
(% pred)
Pinteraction= 0.04 Pinteraction= 0.47
CRP
Figure 3 Estimates (95% CI) of associations between biomarkers and FEV1 in men and women.
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leukocyte count and CRP and leukocyte count and
VCAM-1 remained statically significant also after ad-
justment for cardiovascular comorbidity.
The association between leukocyte count and FEV1
was stronger in men than in women. This result is in ac-
cordance with previous publications from our groups
showing that the association between lung function and
systemic inflammation is stronger in men than in women
[16-19]. The biological explanation for this gender differ-












Figure 4 Estimates (95% CI) of associations between biomarkers andbetween the clinical manifestation and pathophysiology
of lung disease in men and women [37,38]. Women with
COPD have more dyspnea, anatomically smaller airway
lumens with disproportionately thicker airway walls and
less extensive emphysema.
The strength of this study was that data were collected
from a general population and analysed with high-quality,
standardised methods. A wide range of biomarkers
and their relation to lung function was analysed simul-
taneously. There are, however, also limitations of the
study that deserve mention. First, the study had aMen Women
Pinteraction = 0.42
VCAM-1
FVC in men and women.
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of non-participants revealed that the present sample
was representative for the total population. Second, post-
bronchodilator measurements of lung function were not
performed and it was therefore not possible to assess
the association between systemic inflammation and COPD
in a reliable manner. Third, the sensitivity of the method
for measuring IL-1α, IL-1β, IL-4 and IL-10 was insuf-
ficient, as many values were under detection limit. It
should also be noted that the associations found were
fairly weak which indicates that the analysed biomarkers
are not clinically useful at present.
Low lung function in elderly is associated with a shorter
life expectancy [1,2] and morbidity [3-5]. In a another
analysis of the present population we also found that
low lung function was related to autonomic dysfunction
[21], which could contribute to the association between
low lung function and cardiovascular comorbidity. Sys-
temic inflammation is also a likely contributor to the
association between low lung function and morbidity
[14,15]. As the present study was cross-sectional the cause
and effect relationship between systemic inflammation,
lung function and morbidity has to be explored in more
detail in longitudinal studies.Conclusion
Leucocyte count, CRP and VCAM-1 were found to relate
to poorer lung function. A dose related association was
found for the combination leukocyte count and CRP to-
wards FEV1 and leukocyte and VCAM-1 towards FVC.
This indicates that combination of two biomarkers yielded
more information than assessing them one by one when
analysing the association between systemic inflammation
and lung function. The association between systemic in-
flammation and lung function maybe stronger in men
than women.
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